Heminevrin (Clomethiazole)

Heminevrin is indicated for short‑term management of symptoms associated with alcohol withdrawal and for occasional insomnia when other treatments are unsuitable.

• Treatment of acute alcohol withdrawal syndrome under medical supervision.
• Short‑term relief of insomnia in patients requiring a sedative‑hypnotic.
• Adjunct therapy in hospital settings for patients at risk of severe withdrawal complications.
• Use in controlled environments where monitoring of respiratory function is possible.
• May be considered when benzodiazepines are contraindicated or ineffective.

Clomethiazole can produce a range of neurological and systemic effects, some of which are expected and others that require medical attention.

Common

• Drowsiness or sedation.
• Dizziness or light‑headed feeling.
• Headache.
• Nausea or mild gastrointestinal upset.
• Dry mouth.
• Transient visual disturbances.

Serious

• Respiratory depression, especially when combined with other depressants.
• Severe hypotension or cardiovascular instability.
• Paradoxical agitation or confusion.
• Allergic reactions such as rash, itching, or swelling.
• Hepatic dysfunction indicated by jaundice or elevated liver enzymes.
• Seizures in patients with abrupt discontinuation.

When prescribing Heminevrin, clinicians should evaluate patient history and monitor for potential complications.

• Assess respiratory function before initiation, particularly in patients with chronic lung disease.
• Use the lowest effective dose for the shortest duration to reduce dependence risk.
• Avoid use in patients with severe hepatic impairment.
• Caution in the elderly due to increased sensitivity to sedative effects.
• Monitor for signs of withdrawal if therapy is discontinued abruptly.
• Evaluate for concomitant use of other central nervous system depressants.
• Discuss potential effects on psychomotor performance and advise against operating machinery.

Clomethiazole may interact with several drug classes, altering its efficacy or safety profile.

Avoid

• Other CNS depressants (e.g., benzodiazepines, opioids, barbiturates) due to additive respiratory depression.
• Alcohol, which can potentiate sedative effects and increase overdose risk.
• Strong CYP3A4 inhibitors that may raise clomethiazole plasma levels.

Use with caution

• CYP3A4 inducers that could reduce therapeutic effect.
• Antidepressants, particularly SSRIs, which may increase the risk of serotonin syndrome.
• Antihistamines and antihypertensives that can enhance sedation or hypotension.
• Medications affecting hepatic metabolism, requiring dose adjustments or closer monitoring.